Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Supreme Court Slams Allahabad HC For 'Insensitive' Remarks In Attempted Rape Case; Orders Trial To Proceed Under Original Charges
Uttar Pradesh Politics: BSP Chief Mayawati Flags Concerns Over Speedy Voter List Revision; Warns Poor & Migrant Workers May Lose Voting Rights
Congress Leader Rahul Gandhi To Visit Germany From December 15–20
Uttarakhand: Major Fire Breaks Out At Shishu Mandir Vidyalaya In Nainital; No Casualties Reported |VIDEO
